Arrhythmogenic ventricular cardiomyopathy: A paradigm shift from right to biventricular disease

Saguner, Ardan M; Brunckhorst, Corinna; Duru, Firat

Abstract: Arrhythmogenic ventricular cardiomyopathy (AVC) is generally referred to as arrhythmogenic right ventricular (RV) cardiomyopathy/dysplasia and constitutes an inherited cardiomyopathy. Affected patients may succumb to sudden cardiac death (SCD), ventricular tachyarrhythmias (VTA) and heart failure. Genetic studies have identified causative mutations in genes encoding proteins of the intercalated disk that lead to reduced myocardial electro-mechanical stability. The term arrhythmogenic RV cardiomyopathy is somewhat misleading as biventricular involvement or isolated left ventricular (LV) involvement may be present and thus a broader term such as AVC should be preferred. The diagnosis is established on a point score basis according to the revised 2010 task force criteria utilizing imaging modalities, demonstrating fibrous replacement through biopsy, electrocardiographic abnormalities, ventricular arrhythmias and a positive family history including identification of genetic mutations. Although several risk factors for SCD such as previous cardiac arrest, syncope, documented VTA, severe RV/LV dysfunction and young age at manifestation have been identified, risk stratification still needs improvement, especially in asymptomatic family members. Particularly, the role of genetic testing and environmental factors has to be further elucidated. Therapeutic interventions include restriction from physical exercise, beta-blockers, sotalol, amiodarone, implantable cardioverter-defibrillators and catheter ablation. Life-long follow-up is warranted in symptomatic patients, but also asymptomatic carriers of pathogenic mutations.

DOI: https://doi.org/10.4330/wjc.v6.i4.154
Arrhythmogenic ventricular cardiomyopathy: A paradigm shift from right to biventricular disease

Ardan M Saguner, Corinna Brunckhorst, Firat Duru

Ardan M Saguner, Corinna Brunckhorst, Firat Duru, Department of Cardiology, University Heart Center, CH-8091 Zurich, Switzerland

Author contributions: Saguner AM, Brunckhorst C and Duru F equally contributed to this article.

Supported by The Georg and Bertha Schwyzer-Winiker Foundation, Zurich, Switzerland

Correspondence to: Firat Duru, Professor, Department of Cardiology, University Heart Center, Rämistrasse 100, CH-8091 Zurich, Switzerland. firat.duru@usz.ch

Telephone: +41-44-2553565 Fax: +41-44-2554401

Received: December 17, 2013 Revised: February 25, 2014 Accepted: March 13, 2014 Published online: April 26, 2014

Abstract

Arrhythmogenic ventricular cardiomyopathy (AVC) is generally referred to as arrhythmogenic right ventricular (RV) cardiomyopathy/dysplasia and constitutes an inherited cardiomyopathy. Affected patients may succumb to sudden cardiac death (SCD), ventricular tachyarrhythmias (VTA) and heart failure. Genetic studies have identified causative mutations in genes encoding proteins of the intercalated disk that lead to reduced myocardial electro-mechanical stability. The term arrhythmogenic RV cardiomyopathy is somewhat misleading as biventricular involvement or isolated left ventricular (LV) involvement may be present and thus a broader term such as AVC should be preferred. The diagnosis is established on a point score basis according to the revised 2010 task force criteria utilizing imaging modalities, demonstrating fibrous replacement through biopsy, electrocardiographic abnormalities, ventricular arrhythmias and a positive family history including identification of genetic mutations. Although several risk factors for SCD such as previous cardiac arrest, syncope, documented VTA, severe RV/LV dysfunction and young age at manifestation have been identified, risk stratification still needs improvement, especially in asymptomatic family members. Particularly, the role of genetic testing and environmental factors has to be further elucidated. Therapeutic interventions include restriction from physical exercise, beta-blockers, sotalol, amiodarone, implantable cardioverter-defibrillators and catheter ablation. Life-long follow-up is warranted in symptomatic patients, but also asymptomatic carriers of pathogenic mutations.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

Key words: Arrhythmogenic right ventricular dysplasia/cardiomyopathy; Arrhythmias; Ventricular tachycardia; Sudden cardiac death; Implantable cardioverter defibrillator

Core tip: This manuscript constitutes an updated overview about arrhythmogenic ventricular cardiomyopathy (AVC) and describes well the paradigm shift in the understanding of AVC from an isolated right-sided entity to biventricular disease that can present with multiple facets. The most recent advances in molecular and clinical research are discussed, with particular focus on genetic novelties and risk stratification. We believe that this review will help clinicians to better understand the pathomechanisms that lead to AVC, its diagnosis and state-of-the-art therapeutic decision making.

Saguner AM, Brunckhorst C, Duru F. Arrhythmogenic ventricular cardiomyopathy: A paradigm shift from right to biventricular disease. World J Cardiol 2014; 6(4): 154-174 Available from: URL: http://www.wjgnet.com/1949-8462/full/v6/i4/154.htm DOI: http://dx.doi.org/10.4330/wjc.v6.i4.154

INTRODUCTION

Arrhythmogenic ventricular cardiomyopathy (AVC), as
recently re-named by the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA) consensus statement paper[2], is generally referred to as arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D), constituting a hereditary cardiomyopathy usually with an autosomal-dominant inheritance pattern. Its first description by Giovanni Maria Lancisi, the Pope’s physician, dates back to 1736 in his book “De Motu Cordis et Aneurysmatibus”[3]. The first comprehensive description of ARVC/D by Guy Fontaine in 1978 marks a milestone for our current understanding of this heterogeneous disease[4]. Initially, ARVC/D was thought to be an embryological aberration, such as Uhl’s anomaly leading to the original denomination of dysplasia[5]. However, further research shed light on the pathophysiology of ongoing genetically determined myocardial atrophy that did not support the theory of a congenital myocardial absence. Thus, in 1995, ARVC/D was assigned to the World Health Organization’s definition and classification of primary cardiomyopathies[6]. Autopsy studies have been crucial in understanding AVC. Progressive atrophy of the ventricular musculature due to cumulative myocyte loss and infiltration by fibrous and adipose tissue can be observed.

The right ventricle (RV) is primarily affected in AVC, representing the most common form known as ARVC/D, and thus can be referred to as classic AVC[7]. At a later stage, the left ventricle (LV) can also be involved and is often associated with severe disease and a worse prognosis[7]. Advanced molecular genetic studies have identified causative mutations in genes encoding proteins of the intercalated disk, mainly desmosomal proteins[8] that lead to reduced electrical and mechanical stability of the myocardium[9,10]. Subsequent myocardial inflammation, apoptosis and necrosis may occur. Some of these histological changes are currently discussed as potential cases of myocarditis mimicking AVC[11-14]. Because of the genetic basis and the many facets of the disease, the term “ARVC” is somewhat misleading. Particularly as biventricular involvement and less often isolated LV involvement may be present in a substantial proportion of patients[8,15], a broader term such as “arrhythmogenic cardiomyopathy” should be preferred, as already suggested by Gallo et al[16] almost 20 years ago, and as recently proposed by the HRS and the EHRA[1]. However, the cardiology community is still reluctant to accept the proposed new nomenclature, probably because RV involvement constitutes a hallmark of the disease and non-classic forms are difficult to distinguish from non-ischemic dilated cardiomyopathies.

**EPIDEMIOLOGY**

In most parts of the world, phenotypic expression is more common in men than in women (2:3:1)[17,18]. AVC commonly manifests during late childhood or adolescence but can also emerge in the elderly[19,20]. With a general prevalence of 1:2000, which can be higher in certain geographical regions with enhanced genetic prevalence such as the Veneto region or the Greek island Naxos, it is not so rare[21,22]. Recent data indicates that the prevalence is even higher than initially estimated[23]. AVC is recognized as a leading cause of sudden cardiac death (SCD) in young adults ≤ 35 years of age and may account for up to 10% of cardiovascular deaths in the < 65 age group[24,25]. Of note, in one series from northern Italy, AVC accounted for up to 22% of SCD in all young adults ≤ 35 years of age[16,26]. AVC usually first manifests with ventricular tachyarrhythmias (VTA) or SCD. In its most common form ARVC/D, ventricular arrhythmias originate in the RV and thus have left bundle branch block (LBBB) morphology[26,27]. Less often, the primary manifestation can be heart failure without symptomatic arrhythmias. As LV function is often preserved at early stages, ventricular tachycardia (VT) may be asymptomatic as far as it does not degenerate into ventricular fibrillation (VF)[28]. An early concealed phase without gross structural abnormalities is unique among the primary cardiomyopathies. On the contrary, in hypertrophic cardiomyopathy, arrhythmic risk can be ascribed to the underlying myocardial disarray. In dilated cardiomyopathy (DCM), arrhythmias generally concur with significant LV systolic dysfunction[29]. Of note, early AVC may resemble myocardial channelopathies, such as Brugada syndrome (Bs)[30], thus making correct diagnosis and risk stratification difficult.

**DISEASE SUBTYPES**

Classification of AVC into three different subtypes is evolving. AVC in its classic right-dominant form is the most common and best known and referred to as ARVC/D. The non-classic forms were first described by pathologists on autopsy studies and in isolated clinical case reports[31,32]. Through intensive in vivo characterization of affected families, a link to hereditary mutations of the intercalated disk was established[33-35]. LV involvement is increasingly described with a prevalence of up to 76% of cases, which may be attributed to improved diagnostic methods such as genetic testing, high-resolution contrast-enhanced cardiac magnetic resonance tomography (CMR), and recently the new technology of echocardiographic strain imaging[36]. The proposed classification below is simplistic since due to genetic heterogeneity and epigenetic factors, a phenotypic continuum with right- and left-dominant subtypes at opposite ends has to be assumed.

In classic right-dominant ARVC, a dilated RV with fibro-fatty infiltration with no or only minimal LV involvement can be found at autopsy (Figure 1). This fibro-fatty infiltration typically begins subepicardially and may expand transmurally over time[37]. Papillary muscles and trabeculae are generally not involved in this process[38]. Yet, fatty infiltration alone does not constitute a pathognomonic sign of AVC, as a certain amount of epicardial and intramyocardial fat without an increase in fibrous tissue is present in both ventricles, more commonly in the RV, of persons without cardiovascular disease, particu-
larly in the obese and elderly\(^{[17,40,41]}\). Another consistent finding in \(\text{AVC}\) is myocardial atrophy. Myocardial wall thinning, but also thickening, can both be seen on macroscopic examination\(^{[22,40]}\). The subtricuspid region and the thin RV outflow tract (RVOT) are particularly prone to ventricular bulging and aneurysm formation that is present in 20%-50% of autopsy cases of \(\text{ARVC/D}\)\(^{[39]}\). The former concept of early RV apical involvement and the term “triangle of dysplasia” have recently been questioned\(^{[42]}\). Even although not very specific, ventricular aneurysms are strongly associated with the disease. The fact that the interventricular septum is rarely affected by fibro-fatty infiltration is an important disadvantage of endomyocardial biopsies, usually obtained from the septum, which may frequently yield false-negative results\(^{[43]}\). If an affected region can be obtained for histological evaluation, it may reveal both replacement fibrosis, a repair mechanism after myocyte loss, and interstitial fibrosis, a reactive process, e.g., to inflammation\(^{[36,40]}\).

Biventricular \(\text{AVC}\) is characterized by early and parallel involvement of both ventricles that can only be visualized by advanced imaging techniques such as contrast CMR or strain echocardiography\(^{[19,40]}\). Progressive disease is characterized by systolic impairment and biventricular dilation with clinical features of global congestive heart failure. In contrast to other cardiomyopathies with biventricular involvement, ventricular arrhythmias of both right bundle branch block (RBBB) and LBBB configuration are present at an early stage, with around 10% of patients presenting with both\(^{[33]}\).

Left-dominant \(\text{AVC}\) (ALVC) has recently been suggested as a distinct form of \(\text{AVC}\) and is characterized by the early occurrence of LV involvement, while global RV function is preserved\(^{[56]}\). An overlap with idiopathic myocardial fibrosis (IMF) accounting for certain SCD cases in a post mortem series has been reported\(^{[48]}\). Typically, IMF features diffuse interstitial and replacement fibrosis with a predilection for the inferior LV wall in the absence of coronary artery disease and other structural abnormalities. Of note, myocardial infiltration by adipocytes is lacking in IMF. In biventricular disease or ALVC, ventricular arrhythmias may also originate from the LV and thus show a RBBB configuration. Structural and electrocardiographic (ECG) findings are the left-sided analogues to those observed in ARVC/D (Table 1). The RV to LV ratio typically remains < 1.0. To better understand ALVC and its clinical course, future investigations will be required.

**PATHOGENESIS**

Genetically-determined disruption of intercalated-disk integrity is a key factor promoting the development of \(\text{AVC}\) and SCD. This is widely named the “defective desmosome” hypothesis\(^{[46,47]}\). Recent data indicates that loss of desmosomal integrity can substantially affect gap junctions, sodium channel function and electrical propagation at the micro- and nano-scale, thereby promoting ventricular arrhythmias in the absence of overt structural damage\(^{[48]}\). Accordingly, lethal arrhythmias such as VF and polymorphic VT often occur during these concealed early stages, while sustained monomorphic VT occur at later stages, where there is enough substrate for macro-re-entry. Delmar et al\(^{[4]}\) thus have postulated that mutations in desmosomal genes may affect the integrity of other molecular complexes that reside in proximity to desmosomes, such as connexins and voltage gated sodium channels, and are crucial for electrical synchrony. This molecular complex and its interactions have been named the cardiac connexome\(^{[49,50]}\). Yet, genetic mutations in gap junctions such as connexin-43 have not been associated with \(\text{AVC}\) so far\(^{[10,53]}\).

Currently, two theories for the understanding of progressive fibro-fatty replacement of the myocardium exist: (1) inflammation as a response to myocardial injury\(^{[2,25,39]}\). Lymphocytic interstitial infiltrates surrounding foci of necrotic or degenerative myocytes are observed on histopathology. Myocyte cell death may occur via apoptosis or necrosis underlying chronic inflammation. Acute myocyte cell death has also been reported, suggesting acute myocarditis during the disease course\(^{[53]}\). Periodic exacerbations of a previously quiescent disease may be
triggered by such inflammatory episodes and are called “hot phases” of AVC. Occasionally, these phases may clinically present with chest pain, dynamic ECG changes and increased arrhythmic activity[31]. Strenuous physical activity can trigger inflammation as mechanical stress to the impaired intercalated disk leads to myocyte detachment and myocyte cell death[33]. It is important to keep in mind that isolated myocarditis, sarcoidosis, Bs and other diseases can mimic AVC[14], which may prompt further histological and molecular investigations. If molecular genetic analyses or pedigree analyses of affected family members are not performed, a biopsy specimen may be classified as focal myocarditis[36]. Yet, previous studies have indicated a link between AVC and a susceptibility to viral and bacterial myocarditis, particularly in non-hereditary forms[34,35]. The prevalence of viral genome in myocardial biopsies from AVC patients is reported with a broad range from 0% to 75%, but a causal association is difficult to prove. Presence of enteroviral RNA has been reported in tissue from patients with DCM, suggesting an innocent bystander role. Nevertheless, viral presence may play a secondary yet important role in disease progression[47]; and (2) apoptosis following disruption of the intercalated disc[46] with electromechanical instability, as indicated by detection of fragmented DNA, expression of protease CPP-32 by immunohistochemistry and positive Tc-annexin V scintigraphy in vivo[31,43,47,58]. These histological disarrangements create a substrate for electrical re-entrant phenomena and delayed ventricular activation triggering ventricular arrhythmias. Of note, AVC can cause ventricular arrhythmias and SCD in the absence of gross macroscopic abnormalities, histological and molecular examinations are important to establish a post-mortem diagnosis[49]. Other investigators observed that epicardium-derived cell cultures obtained from neonatal hearts lacking plakophilin-2 (PKP2), an important desmosomal gene, revealed enhanced cell migration velocity and proliferation, leading to the hypothesis that desmosomal mutations may cause infiltration of fibroblasts and adipocytes from the epicardial cell layer into the myocardium[66]. This hypothesis is consistent with the frequent clinical observation that fibro-fatty infiltration progresses from the epicardium towards the endocardium.

### GENETICS

Analyses of the first- and second-degree relatives of patients suggest that up to 50% of AVC cases are familial[61-65]. AVC is most commonly inherited as a Mendelian autosomal dominant trait with incomplete penetrance[46,47], although two autosomal recessive forms have been described[63-65]. To date, 12 different AVC loci are reported in the Online Mendelian Inheritance in Man (Table 2)[66]. Compound and digenic heterozygosity has been recently suggested, indicating that in some cases more than one pathogenic allele may be involved in the disease process[66,67,68]. As penetrance is incomplete, genetically affected relatives often demonstrate variable and mild phenotype and the prevalence of familial disease is often underestimated in clinical practice[61,62]. The fact that AVC can be inherited has been known since 1982 after the description of 24 adult cases, two in the same family, by Marcus et al[69]. Six years later, the autosomal dominant pattern of inheritance with incomplete penetrance and variable expression was demonstrated in a study of nine Italian families[70]. As patients with fully penetrant cardiomyopathy and readily discernible features of the palms, plantar fascia and hair were clustered in families on the Greek island Naxos, an autosomal recessive mutation in the desmosomal protein junction plakoglobin (JUP) was finally discovered, which became known as Naxos disease. Myocytes and epidermal cells share similar intercalated disks (desmosomes and fascia adherens) and are both exposed to high shear stress, the

### Table 1  Characteristics of arrhythmogenic ventricular cardiomyopathy

| Classic right dominant form (ARVC/D) | Left dominant form |
|-------------------------------------|-------------------|
| 12-lead surface ECG                 |                   |
| Intraventricular conduction delay in V1-V3 | Leftward QRS axis (≤ 0°) |
| QRS complex prolongation V1-V3      | ε-like waves in inferior or lateral leads |
| ε wave in V1-V3                     | LBBB              |
| (Incomplete) RBBB                   | Inverted T-waves in infero-lateral leads |
| Inverted T-waves in V1-V3           | Inverted T-waves V1-6 with biventricular involvement |
| Inverted T-waves in V1-V6 with biventricular involvement | - |
| ST elevation in V1-V3               | ST elevation in V1-V3 |
| Poor R wave progression             | Poor R wave progression |
| Signal-averaged ECG                 |                   |
| Arrhythmia                          |                   |
| PVC/VT of LBBB configuration         | PVC/VT of RBBB configuration |
| Ventricular volumes                 |                   |
| Mild to severe RV-dilation ± dysfunction | Mild to severe LV-dilation ± dysfunction |
| RV/LV volume ratio                  |                   |
| ≥ 1.2, increases with disease expression | < 1.0 |
| Other imaging abnormalities          |                   |
| Regional wall motion abnormalities in RV | Regional wall motion abnormalities in LV |
| RV aneurysms                        | Non-compacted appearance |
| Fat/LGE in RV myocardium            | LGE in the subepicardial and midwall LV myocardium |
| Genetics                            |                   |
| Affected genes currently known to be associated with AVC | Association with TMEM43 and phospholamban mutations[10] |

Adapted from Jacoby et al[46]. ARVC/D: Arrhythmogenic right ventricular cardiomyopathy/dysplasia; ECG: Electrocardiogram; ε: Epsilon; LBBB: Left bundle branch block; LGE: Late gadolinium enhancement; LV: Left ventricle; PVC: Premature ventricular contraction; RBBB: Right bundle branch block; RV: Right ventricle; VT: Ventricular tachycardia; AVC: Arrhythmogenic ventricular cardiomyopathy; TMEM43: Transmembrane protein 43.
heart particularly during strenuous physical activity and increased cardiac workload. Thus, it has been assumed that common genes encoding proteins of the intercalated disk might be responsible for AVC. In 1994, the first chromosomal locus (14q23-q24) for autosomal dominant AVC was reported in Italy.[47] Linkage analyses shed light on its genetic heterogeneity with sequential discovery of several loci on chromosomes 1, 2, 3, 6, 10, 12, 14, 17 and 18 (Table 2). Most frequently, mutations in genes encoding components of the cardiac desmosome, an important protein complex of the intercalated disk (Figure 2), are associated with AVC, resulting in impaired intercalated-disk integrity.[62,67,68]. The pathogenic importance of desmosomal mutations was confirmed by electron microscopy and immunohistochemistry.[12,56]. Intercellular junctions consist of a core region that mediates cell-cell adhesion and a plaque region that provides attachment to the intermediate filaments within the myocyte. Three groups of desmosomal proteins are known: (1) transmembrane desmosomal cadherins including desmocollins and desmogleins; (2) armadillo proteins (plakoglobin and plakophilin) and desmoplakin. This interaction is crucial for myocardial mechanical and electrical stability. Mutations in arrhythmogenic right ventricular cardiomyopathy mostly affect desmosomal proteins.

Table 2 Arrhythmogenic ventricular cardiomyopathy classification, from OMIMTM Online Mendelian inheritance in Man

| AVC subtype | Chromosome/locus | Mode of transmission | Encoded protein |
|-------------|------------------|---------------------|----------------|
| ARVC/D 1    | 14q23-q24        | Autosomal-dominant  | TGFβ3          |
| ARVC/D 2    | 1q21-q23         | Autosomal-dominant  | RyR2           |
| ARVC/D 3    | 1q22-q23         | Autosomal-dominant  | -              |
| ARVC/D 4    | 2q32             | Autosomal-dominant  | TTN            |
| ARVC/D 5    | 3p23             | Autosomal-dominant  | TMEM43         |
| ARVC/D 6    | 10p12-p14        | Autosomal-dominant  | -              |
| ARVC/D 7    | 10q22            | Autosomal-dominant  | -              |
| ARVC/D 8    | 8p24             | Autosomal-dominant  | DSP            |
| ARVC/D 9    | 12p11            | Autosomal-dominant  | PKP2           |
| ARVC/D 10   | 18q12            | Autosomal-dominant  | DSG2           |
| ARVC/D 11   | 18q12.1          | Autosomal-dominant  | DSC2           |
| ARVC/D 12   | 17q21            | Autosomal-dominant  | JUP            |
| Naxos disease| 17q21            | Autosomal-recessive | JUP            |

AVC: Arrhythmogenic ventricular cardiomyopathy; ARVC/D: Arrhythmogenic right ventricular cardiomyopathy/dysplasia; TGF: Transforming growth factor; RyR2: Ryanodine receptor 2; TTN: Titin; TMEM43: Transmembrane protein 43; DSP: Desmoplakin; PKP2: Plakophilin-2; DSG2: Desmocollin-2; DSC2: Desmocollin-2; JUP: Junction plakoglobin.

![Figure 2 Molecular model of the desmosome: in the desmosomal complex the intermediate filaments of the cytoskeleton (desmin in the heart) are linked to the transmembranous cadherins (desmocollin and desmoglein) via armadillo proteins (plakoglobin and plakophilin) and desmoplakin. This interaction is crucial for myocardial mechanical and electrical stability. Mutations in arrhythmogenic right ventricular cardiomyopathy mostly affect desmosomal proteins.](image-url)
MODIFIER GENES AND ENVIRONMENTAL FACTORS

Although a plethora of pathogenic mutations exists, these mutations cannot account for the entire broad spectrum of disease expression. Data from the Newfoundland founder population and populations from the Dutch and Swiss ARVC/D registries show a strong male predominance of disease expression. A modifier effect of testosterone has been discussed. Yet, this male predominance has not been confirmed in the Johns Hopkins ARVC/D cohort, which may be associated with similar exercise levels among males and females in the United States. Nevertheless, outcomes were strongly gender dependent in all of those cohorts, with male gender constituting an independent risk factor for adverse outcomes. In one study, 67% of family members showed discordant disease patterns between RV and LV involvement. Recent data pointing at the importance of compound and digenic heterozygosity indicates that modifier genes may account for residual variation and disease severity. The first evidence for environmental influences in AVC arose from monozygotic twin studies, where differences were reported in symptom onset, structural severity and arrhythmic risk. Strenuous physical activity seemed to play an important role in these four cases. These preliminary observations were confirmed in two recent studies, in which endurance training and frequent exercise were associated with earlier disease manifestation and disease severity. Future studies will be crucial to distinguish between pathogenic mutations and innocent bystander mutations and to define the role of epigenetic factors in disease manifestation and progression. As recently proposed by the HRS/EHRA consensus statement, genetic testing should only be performed if the signal-to-noise ratio is expected to be $>$ 10.$^{[10]}$

| Table 3 Future candidate proteins for arrhythmogenic ventricular cardiomyopathy |
|-------------------------------|-------------------------------|
| **Encoded protein**           | **Components of the desmosome** |
| Plectin                       | Emerin                        |
| Emerin                        | N-cadherin                    |
| α-catenin                     | Connexin 43                   |
| Laminin receptor-1            | Myotonic dystrophy protein kinase-1 |
| Components of the adherens junction | Laminin receptor-1          |
| Components of the gap junction | Laminin receptor-1          |
| Components of dystrophin-glycoprotein complex | Laminin receptor-1          |

Figure 3 Monomorphic sustained ventricular tachycardia with left bundle branch block morphology and superior axis (I, III, aVF negative), a major criterion for arrhythmogenic right ventricular cardiomyopathy/dysplasia according to the revised 2010 task force criteria.

CLINICAL PRESENTATION

AVC has a reported community-based prevalence of 1 in 2000 and thus cannot be classified as a “rare” disease according to the 2007 European definition. These numbers reflect the importance of appropriate diagnostic tools as it is often underdiagnosed, particularly in early and mild cases. The above mentioned non-classic subtypes are usually not considered or misattributed as DCM. Some forms mimic myocarditis. Early disease with arrhythmias but without overt structural changes may be misjudged as idiopathic VT or ventricular ectopy. In the elderly, AVC is rarely considered as a differential diagnosis, which is certainly a false assumption. All these aspects infer that real-world prevalence is higher. In the following section, we provide an overview of clinical symptoms and signs that shall increase awareness of the disease, particularly in non-classic forms, for timely diagnosis and prevention of SCD. AVC should be suspected if the following symptoms or signs occur: (1) palpitations; (2) presumably arrhythmic presyncope or syncope; (3) VT with LBBB morphology; (4) aborted SCD. Palpitations and (pre)syncope are the most frequent symptoms. A high clinical suspicion should be raised if these symptoms correlate with premature ventricular contractions (PVC) or VT with LBBB morphology, particularly with a superior axis (Figure 3). However, ALVC or biventricular disease can present with VT with RBBB morphology or both (Table 1, Figure 3). The presence of monomorphic VT is associated with late disease stages, although gross structural changes are not mandatory. Recently, disease severity, VT frequency and early onset of VT have been associated with the presence of common desmosomal mutations, particularly if more than one pathogenic variant was present. Up to 25% of patients present with supraventricular tachycardia (SVT), most frequently atrial fibrillation, which is associated with male gender, increasing age and left atrial enlargement in AVC. SVT are very important as they are associated with inappropriate implantable cardioverter defibrillator (ICD) shocks.

| I   | II  | III | aVR | aVL | aVF |
|-----|-----|-----|-----|-----|-----|
| V1  | V2  | V3  | V4  | V5  | V6  |

| Table 3 Future candidate proteins for arrhythmogenic ventricular cardiomyopathy |
|-------------------------------|-------------------------------|
| **Encoded protein**           | **Components of the desmosome** |
| Plectin                       | Emerin                        |
| Emerin                        | N-cadherin                    |
| α-catenin                     | Connexin 43                   |
| Laminin receptor-1            | Myotonic dystrophy protein kinase-1 |
| Components of the adherens junction | Laminin receptor-1          |
| Components of the gap junction | Laminin receptor-1          |
| Components of dystrophin-glycoprotein complex | Laminin receptor-1          |

Figure 3 Monomorphic sustained ventricular tachycardia with left bundle branch block morphology and superior axis (I, III, aVF negative), a major criterion for arrhythmogenic right ventricular cardiomyopathy/dysplasia according to the revised 2010 task force criteria.
and an increased risk of both heart failure and death. Furthermore, atrial arrhythmias present at a younger age than in the general population[8]. It is not rare that AVC first manifests as SCD, with some authors reporting an annual incidence of 9%/10]. Whereas some authors report that SCD occurs preferentially during strenuous physical activity[8,28], according to others it may often occur in the sedentary state[13,25]. In ARVC/D caused by TMEM43 mutations, enhanced sympathetic activity as a trigger for lethal arrhythmias is established[8]; (5) chest pain with or without dynamic ST elevation/T-wave changes on 12-lead surface ECG ± rise in cardiac biomarkers; and (6) presumed DCM with early onset and frequent ventricular arrhythmias. Precordial T-wave inversions beyond V1 after puberty (Table 1, Figure 4) and T-wave inversions in the right precordial leads (Figure 4) may potentially be benign, particularly before puberty. Their prevalence among athletes and sedentary controls is similar[89], suggesting that this is not a training-related phenomenon. According to recent recommendations, a further evaluation with transthoracic echocardiography (TTE) may be performed after puberty. If imaging is inconclusive, regular follow-up by serial clinical examinations, ECG and TTE can be performed as structural alteration may become apparent after several years[90]. RV failure with dyspnea and signs of right sided heart failure are rather rare and reported in up to 6% of patients at initial presentation. If the LV is involved, congestive heart failure may occur. Importantly, the clinician should be aware that AVC cannot be excluded by the absence of structural abnormalities as arrhythmias often occur in the “concealed phase” and structural abnormalities may follow after years. In a review reporting 37 families with AVC index patients, only 151 of 365 family members had clinically manifested disease and 17 family members were healthy despite a pathogenic mutation[20]. Thus, genetic screening of family members may help to identify AVC, although a negative test does not exclude it.

**Revised 2010 task force criteria**

Currently, no gold standard to establish or exclude the diagnosis of AVC exists. In 2010, the original 1994 task force criteria (TFC) for diagnosis of ARVC/D by Marcus et al[25] were revised in order to enhance diagnostic sensitivity and particularly to improve identification of affected asymptomatic family members[93]. The importance of pathogenic mutations was acknowledged and precise cutoff values for imaging and histological evaluation were provided. The impact of these changes is currently being evaluated. Some investigators report an increased diagnostic yield with the revised TFC[89,90], while others could not demonstrate a benefit[96,97]. It is important to keep in mind that these TFC only apply to ARVC/D with or without LV involvement. The revised TFC assign the findings into six categories (Table 4): (1) global and/or regional myocardial dysfunction and structural abnormalities; (2) histological characterization; (3) repolarization abnormalities on 12-lead surface ECG; (4) depolarization abnormalities on 12-lead surface ECG; (5) arrhythmias; and (6) family history and genetics.

Definite diagnosis requires 2 major criteria, 1 major and 2 minor criteria, or 4 minor criteria from different categories. ARVC/D is considered “borderline” if 1 major and 1 minor criterion, or 3 minor criteria are present. ARVC/D is still “possible” if 1 major criterion or 2 minor criteria are present. For each individual, comprehensive non-invasive evaluation is necessary. This includes a thorough clinical history and examination, pedigree analysis, 12-lead surface ECG, TTE with detailed assessment of the RV, CMR, stress testing in order to induce arrhythmias, and Holter ECG monitoring. If suspicion remains high and symptoms are rare, event recorders and invasive procedures may be needed.

**Physical examination**

Fifty percent of patients will have a normal physical exam. The other 50% will show abnormalities such as giant a-waves on the jugular veins, tricuspid regurgitation murmur, a fixed splitting of S2, and right-sided S3-S4 at the left sternal border with augmentation during inspiration in case of RV dilation[80,89].

**12-lead surface ECG and signal-averaged ECG**

An abnormal 12-lead surface ECG will be present in about 50% of patients with ARVC/D. In one study, ECG was abnormal in 90% of patients after a follow-up period of 6 years[90]. Abnormalities include epsilon waves, a QRS duration ≥ 110 ms in V1-V3, and T-wave inversions in the right precordial leads (Figure 4). A prolonged terminal activation duration (measured from the nadir of the S wave until the end of the QRS complex) in V1-V3 ≥ 55 ms is considered as a minor criterion for ARVC/D and has been reported as the first sign in young asymptomatic family members[85,62,100]. However, interpretation of ECG findings, apart from T-wave inversions, significantly var-
Residual myocytes 60%-75% by morphometric analysis with fibrous VT of LBBB morphology with superior axis T-wave inversions V1-V2 or V4-V6 (in absence of complete RBBB) SAECG with late potentials (if QRS complex on standard surface ECG < 110 ms) or terminal activation duration of QRS VT of RVOT configuration, LBBB morphology with inferior axis or of unknown axis TTE regional RV akinesia, dyskinesia, or aneurysm and 1 of the following criteria (end diastole)

ARVC/D in a first-degree relative who meets current TFC T-wave inversions V1-V3 or beyond (in absence of complete RBBB) Epsilon wave (reproducible low-amplitude signals between end of QRS complex to onset of the T-wave) in V1 to V3 TTE regional RV akinesia, or dyskinesia and 1 of the following criteria (end diastole) Suspected ARVC/D in a first-degree relative—premature SCD (< 35 years of age) due to suspected ARVC/D in a first-degree relative

Table 4 Revised (2010) task force criteria for diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia, adapted from Marcus et al[92]

| Structural alterations | Major |
|------------------------|-------|
| TTE regional RV akinesia, dyskinesia, or aneurysm and 1 of the following criteria (end diastole) | PLAX RVOT ≥ 32 mm [(PLAX/BSA) ≥ 19 mm/m²] |
| PSAX RVOT ≥ 36 mm [(PSAX/BSA) ≥ 21 mm/m²] |
| CMR regional RV akinesia, dyskinesia, or dysynchronous RV contraction and 1 of the following criteria (end diastole) | RV end-diastolic volume/BSA ≥ 110 mL/m² (♂) or ≥ 100 mL/m² (♀) |
| Or RV fractional area change ≤ 33% |
| RV angiography regional RV akinesia, dyskinesia, or aneurysm |

| Minor |
|-------|
| TTE regional RV akinesia, or dyskinesia and 1 of the following criteria (end diastole) | PLAX RVOT ≥ 29-31 mm [(PLAX/BSA) ≥ 16-18 mm/m²] |
| PSAX RVOT ≥ 32-35 mm [(PSAX/BSA) ≥ 18-20 mm/m²] |
| CMR regional RV akinesia, dyskinesia, or dysynchronous RV contraction and 1 of the following criteria (end diastole) | RV end-diastolic volume/BSA ≥ 100-109 mL/m² (♂) or ≥ 90-99 mL/m² (♀) |
| Or RV ejection fraction > 40%-44% |
| Histopathology (endomycocardial biopsy) |

| Major |
|-------|
| Residual myocytes < 60% by morphometric analysis with fibrous replacement of the RV free wall myocardium ≥ 1 sample, with or without fatty replacement |
| Residual myocytes 60%-75% by morphometric analysis with fibrous Replacement of the RV free wall ≥ 1 sample Re polarization abnormalities (> 14 years of age) |

| Minor |
|-------|
| Residual myocytes 60%-75% by morphometric analysis with fibrous Replacement of the RV free wall ≥ 1 sample |

| Major |
|-------|
| T-wave inversions V1-V3 or beyond (in absence of complete RBBB) T-wave inversions V1-V2 or V4-V6 (in absence of complete RBBB) T-wave inversions V1-V4, if complete RBBB present Depolarization abnormalities |

| Minor |
|-------|
| Epsilon wave (reproducible low-amplitude signals between end of QRS complex to onset of the T-wave) in V1 to V3 |

| Minor |
|-------|
| SAECG with late potentials (if QRS complex on standard surface ECG < 110 ms) or terminal activation duration of QRS ≥ 55 ms in V1, V2 or V3 |

| Arhythmias |
|-----------|
| VT of LBBB morphology with superior axis |
| VT of RVOT configuration, LBBB morphology with inferior axis or of unknown axis ≥ 500 PVC per 24 h (holter) Family history |

| Major |
|-------|
| ARVC/D in a first-degree relative who meets current TFC ARVC/D confirmed pathologically at autopsy or surgery in a first-degree relative Identification of a pathogenic mutation categorized associated with ARVC/D in an index patient |

| Minor |
|-------|
| Suspected ARVC/D in a first-degree relative-premature SCD (< 35 years of age) due to suspected ARVC/D in a first-degree relative ARVC/D confirmed pathologically or by current TFC in second-degree relatives |

Definite diagnosis: two major or one major and two minor criteria or four minor from different categories; Borderline diagnosis: one major and one minor or three minor criteria from different categories; Possible diagnosis: one major or two minor criteria from different categories. BSA: Body surface area; CMR: Cardiac magnetic resonance tomography; LV: Left ventricle; PLAX: Parasternal long-axis view; PSAX: Parasternal short-axis view; RBBB: Right bundle branch block; RVOT: Right ventricular outflow tract; RV: Right ventricle, TTE: Transthoracic echocardiogram, PVC: Premature ventricular contraction VT: Ventricular tachycardia; SAECG: Signal-averaged electrocardiographic; LBBB: Left bundle branch block; ARVC/D: Arrhythmogenic right ventricular cardiomyopathy/dysplasia; TFC: Task force criteria; SCD: Sudden cardiac death.

Stress testing

Exercise can induce ventricular arrhythmias and is important in patients with suspected AVC. However, VT with LBBB morphology and inferior axis can occur in both ARVC/D and idiopathic RVOT-VT without underlying structural abnormalities[105]. A recent study has proposed ECG criteria and a scoring system to distinguish between the two entities[106].

Transthoracic echocardiography

In many centers, TTE constitutes the initial imaging tool for evaluation of patients with suspected AVC and for screening family members as it is readily available and

ies among observers (unpublished data as yet from our group). This is particularly true for what is considered an epsilon wave. A limitation of T-wave inversions is the fact that they can also be found in healthy individuals, patients with anterior ischemia or RV hypertrophy[99,101].

A recent study highlighted the importance of serial ECG evaluations as dynamic ECG changes occurred in 23% of patients over a median follow-up period of 34 mo, but these were not paralleled by structural abnormalities[102]. Fibro-fatty infiltrations disrupt the electrical continuity of myocardial fibers. This leads to fragmentation and delay of ventricular depolarization (zig-zag pathways). On the surface, this may be visible as QRS fragmentation[103], late ventricular potentials of small amplitude such as epsilon waves[104], or late potentials recorded by signal-averaged ECG (SAECG)[105,106]. An abnormal SAECG (a minor criterion) indicates progressive disease and may predict VT, although a recent study has questioned the latter[28,106]. SAECG may not be sensitive enough to detect early forms of AVC[28].

Stress testing

Exercise can induce ventricular arrhythmias and is important in patients with suspected AVC. However, VT with LBBB morphology and inferior axis can occur in both ARVC/D and idiopathic RVOT-VT without underlying structural abnormalities[105]. A recent study has proposed ECG criteria and a scoring system to distinguish between the two entities[106].

Transthoracic echocardiography

In many centers, TTE constitutes the initial imaging tool for evaluation of patients with suspected AVC and for screening family members as it is readily available and
of LGE within the RV myocardium because of the thin RV and possible confusion with fat. The main difference in CMR criteria compared to the 1994 criteria constitutes the quantification of RV dilation and RV function. CMR plays an important role in diagnosing AVC (Figure 5) but consensus guidelines for non-classic forms are eagerly awaited. Some authors emphasize the importance of combining TTE with CMR to increase diagnostic yield. New diagnostic tools for detection of early diastolic and systolic abnormalities such as three-dimensional echocardiography, strain echocardiography and CMR tagging could facilitate early diagnosis of ARVC/D. The promising results of these preliminary studies[117-129] will have to be validated in large prospective studies.

**RV angiography**

RV angiography is considered a very useful test to diagnose classic forms of AVC and to evaluate RV function[123,124]. Its positive predictive value is above 85%, with a negative predictive value of 95%[89]. Technical aspects of the procedure can be found at arvd.org. Good quality images allow global and regional analyses of morphology and wall motion. RV angiography also has certain limitations that explain why it is not widely used in clinical practice. Clinicians want to offer non-invasive strategies without ionising radiation, particularly if patients are young. Additionally, serial follow-up RV angiographies for monitoring disease progression are difficult to perform. It is important to remember that according to the revised 2010 TFC, with all three imaging techniques, hypokinesia is no longer considered diagnostic.

**Electrophysiological study and electroanatomical voltage mapping**

Arrhythmias can be induced during an electrophysiological study (EPS) with programmed ventricular stimulation. Induction of clinical VT can guide ablation. The susceptibility for arrhythmias, arrhythmia detection, ICD treatment algorithms and efficacy of antiarrhythmic drugs can be assessed. Electroanatomical voltage mapping (EAM) is a technique using electrophysiological catheters to measure local myocardial voltages. After obtaining several hundred points, a voltage map can be reconstructed. According to several studies, healthy RV myocardium displays bipolar voltages > 1.5 mV[125-127]. In myocardium infiltrated by fibro-fatty tissue, abnormally low voltages with a longer duration, splitting and fractionation of signals can be found. Myocardial voltage maps are usually obtained from the endocardium but epicardial measurements after puncturing the pericardial sac are also feasible. EAM has been shown to be safe and to improve outcomes of VT ablation in ARVC/D[128-131]. The diagnostic and prognostic utility of EAM has not yet been implemented in the current TFC. Larger prospective studies may consolidate the role of EAM in the diagnostic armamentarium[123,132,133].

**Endomyocardial biopsy**

Endomyocardial biopsy (EMB) was considered the di-
agnostic gold standard for AVC for a long time. It may allow confirmation of AVC in an index patient and exclude potential differential diagnoses such as sarcoidosis or Chagas disease. However, EMB are commonly taken from the thicker RV septum to assure a safe procedure. It was recognized that the septum is often spared by fibro-fatty infiltration and thus often yields false-negative results[132,134]. Nevertheless, septal EMB can identify other conditions such as sarcoidosis, myocarditis and IME. EMB from diseased regions is problematic as these regions are often difficult to reach, very thin and sample acquisition carries an increased risk of perforation and tamponade[1]. Histological analysis should be performed by an expert cardiac pathologist who judges the amount of surviving myocytes and fibro-fatty replacement. The results can be allocated as one major or one minor criterion according to the revised TFC. As AVC is patchy, several biopsies should be obtained. EAM-guided biopsies taken from low-voltage areas may improve diagnostic yield and better distinguish between myocarditis or sarcoidosis[8,47,136]. Serious concerns remain about the hazards of sampling thin areas, although complication rates in preliminary studies were low[14]. Moreover, EAM-guided EMB may be of limited value in early stages of AVC when serious arrhythmias occur in the absence of gross structural abnormalities. Additional immunohistochemical staining of the intercalated disk, e.g., with plakoglobin, may turn into a valuable tool for pathologists in the future but results vary much depend on the protocols used[12]. Confirmation of typical histological changes by cardiac surgery or necropsy can help to confirm the diagnosis and exclude differential diagnoses.

**Genetic testing**

A consensus statement from the HRS and the EHRA regarding genetic testing in AVC was published recently[1]. The major purposes of genetic testing are to confirm AVC in probands with a high (Class II a recommendation, level of evidence C) or intermediate (at least 1 major or 2 minor criteria; Class II b recommendation, level of evidence C) clinical suspicion and to identify genetically-affected relatives harboring the pathogenic mutation (Class I recommendation, level of evidence C), particularly those without overt disease. Genetic testing in probands fulfilling only one minor criterion is not recommended. A family background and identification of a pathogenic mutation has been demonstrated in up to 50%, while in a family background and identification of a pathogenic mutation 50% may turn into a valuable tool for pathologists in the future but results vary much depend on the protocols used[12]. Confirmation of typical histological changes by cardiac surgery or necropsy can help to confirm the diagnosis and exclude differential diagnoses.

**Differential Diagnosis**

Idiopathic RVOT-VT is a major non-hereditary differential diagnosis that has to be distinguished from ARVC/D. This is often demanding, particularly in the early stages of AVC[14]. RVOT-VT is not associated with structural heart disease and thus has a more benign course. Its etiology is unclear, although in one study a somatic mutation in the inhibitory G protein Gai2 was identified by EMB from the arhythmic focus[142]. In RVOT-VT, 12-lead surface ECG and SAECG are normal during sinus rhythm. It is characterized by repetitive monomorphic VT of a single morphology with LBBB morphology and an inferior axis. Similar VT morphologies can be found in patients with ARVC/D. 12-lead ECG scoring systems to differentiate both types of VT have recently been proposed[108]. In ARVC/D the duration of the QRS complex during VT is usually longer (≥ 120 ms in lead I) [1]. Notching of the QRS and preexcitation in lead V6 may exclusively be seen in ARVC/D[144]. RVOT-VT is difficult to induce by programmed ventricular stimulation during EPS, particularly in the absence of isoproterenol[135]. It responds well to beta-blockers or verapamil and ablation after successful mapping is usually curative. EAM demonstrates normal voltages. CPVT is caused by mutations in the RyR2 gene, which has also been described in ARVC/D subtype 2. CPVT is characterized by effort-induced polymorphic VT in patients with structurally normal hearts. Genetic analysis, a positive family history, EAM and EMB can help to differentiate AVC and regional myocarditis[14]. Myocardial involvement in sarcoidosis can mimic ARVC/D and the changes, ventricular arrhythmias and ventricular abnormalities have to be considered[58]. Yet, the identification of pathogenic mutations may be useful in the differential diagnosis of AVC and phenocopies, such as myocarditis, idiopathic RVOT tachycardia, DCM, muscular dystrophies, IME or sarcoidosis[53]. Cascade genetic screening of relatives may offer another strategy to serial non-invasive cardiovascular evaluation of family members. Current guidelines[147] do not recommend genetic testing for risk stratification and therapeutic decision making in AVC because study results regarding the ability of genotyping to detect malignant mutations associated with an increased susceptibility to potentially lethal arrhythmias have been conflicting[6,62,148,199]. Recent large scale studies[8,62] indicate an association between positive mutation carrier status and early disease onset. Thus, genotyping of younger family members should strongly be encouraged. This might be particularly important for patients carrying digenic or compound heterozygote mutations that are reported in up to 18% of the AVC population studied and have been associated with a stronger phenotype[19]. Issues such as the availability of genetic counselling in a multidisciplinary setting[141], low-probability mutations[136] genetic testing for “low-probability” AVC, psychological repercussions of young patients, and costs need to be considered before performing genetic screening[79].
increased risk of SCD compared to non-athletes and
sion. Young competitive athletes with AVC have a 5-fold
to early disease manifestation and rapid disease progres
this population
10 years and severe LV involvement is often present in
one study has shown that 7% of AVC patients received
ure symptoms; and (4) end-stage heart failu
occurred during which patients are asymptomatic and structural
(59%) and VTA (29%) 19 years. Most patients died of progressive heart failure
is currently estimated to be around 1%-3% per year. In
Although AVC is a progressive disease, the individual
disease course can vary considerably. The mortality rate
is currently estimated to be around 1%-3% per year. In
one study, after 8 years of mean follow-up, total mortality
was approximately 20% and the mean age at death 54 ±
19 years. Most patients died of progressive heart failure
(59%) and VTA (29%)[159]. The presence of gross structural abnormalities favors AVC and mutations in
SCNSA are very rare in AVC. Further differential diagnoses include RV infarction, pulmonary hypertension, congenital left-to-right shunts, Chagas disease and Uhl’s disease (congenital hypoplastic RV).

DISEASE COURSE AND PROGNOSIS

Although AVC is a progressive disease, the individual
disease course can vary considerably. The mortality rate
is currently estimated to be around 1%-3% per year. In
one study, after 8 years of mean follow-up, total mortality
was approximately 20% and the mean age at death 54 ±
19 years. Most patients died of progressive heart failure
(59%) and VTA (29%)[159]. The presence of gross structural abnormalities favors AVC and mutations in
SCNSA are very rare in AVC. Further differential diagnoses include RV infarction, pulmonary hypertension, congenital left-to-right shunts, Chagas disease and Uhl’s disease (congenital hypoplastic RV).

DISEASE COURSE AND PROGNOSIS

Although AVC is a progressive disease, the individual
disease course can vary considerably. The mortality rate
is currently estimated to be around 1%-3% per year. In
one study, after 8 years of mean follow-up, total mortality
was approximately 20% and the mean age at death 54 ±
19 years. Most patients died of progressive heart failure
(59%) and VTA (29%)[159]. The presence of gross structural abnormalities favors AVC and mutations in
SCNSA are very rare in AVC. Further differential diagnoses include RV infarction, pulmonary hypertension, congenital left-to-right shunts, Chagas disease and Uhl’s disease (congenital hypoplastic RV).

SCD in patients with AVC is difficult to predict and often occurs without alarming symptoms. The only reliable strategy for SCD prevention is the implantation of an ICD, with an annual incidence of appropriate ICD interventions among AVC patients of 5%-22%, demonstrating its importance for these patients. Thus, in secondary prevention after aborted SCD, VF or sustained VT, ICD implantation is recommended[87,147]. Besides aborted SCD, VF and sustained VT, other potential risk factors for SCD or appropriate ICD therapy (a surrogate marker for SCD) have been suggested: (1) syncope (DARVIN 2 study)[93], (2) left ventricular dysfunction[76,153], (3) young age at presentation[82,157] and young age per se[47,54], (4) RV structural abnormalities fulfilling 2010 TFC[47,154]; (5) severe tricuspid regurgitation[7], (6) particular genetic variants[62,63,67]; (7) presence of non-sustained VT[150], (8) male gender[79]; (9) proband status[79]; (10) frequent PVC[79]; and (11) presence of precordial T-wave inversions[79].

It is important to recognize that the use of appropriate ICD therapy due to sustained VT or VF as a surrogate for SCD can result in an overestimation of this endpoint. Whether in the absence of arrhythmic syncope or significant ventricular arrhythmias the other potential risk factors are consistently related to an adverse arrhythmic outcome and require prophylactic ICD therapy remains to be determined by future studies. Of note, young patients may suffer from neurocardiogenic syncope, making differential diagnosis difficult and its prognostic value elusive. T-waves in the precordial and inferior leads often become negative with progression of AVC and a greater extent of precordial negative T-waves are associated with more severe RV dilation and dysfunction[160]. Recently, the Johns Hopkins group found that 88% of patients with documented sustained VTA exhibited an abnormal ECG. A total of 122 (84%) subjects demonstrated T-wave inversions in the precordial leads with 97 of them extending to lead V3 and beyond, while depolarization abnormalities such as epsilon waves were present only in a minority of patients[161]. The same group found that the presence of T-wave inversions in ≥ 3 precordial T-wave leads was an independent predictor of adverse events during follow-up[159]. An Italian group has also demonstrated a link between the extent of negative T-waves and ventricular arrhythmic events during follow-up[157]. Although a class IIb recommendation, the role of EPS with programmed ventricular stimulation for risk stratification in AVC is less well established and conflicting data about its prognostic significance exist[45,64,90,158]. Differ-
ences in the studied patient population may be influenced by disease severity and differences in study design may have led to discrepant results. A positive family history of SCD in asymptomatic patients does not seem to increase their individual risk for lethal arrhythmias. Guidelines do not support genetic testing for risk stratification in AVC[8] and genotype-phenotype correlation studies so far have not consistently been able to show that genotyping is able to detect mutations specifically associated with an increased susceptibility to life-threatening arrhythmic events. However, recent data indicates that certain pathogenic mutations (e.g., plakoglobin in Naxos disease, RyR2 and TME-43) may increase the risk for SCD[8,26,7]. These preliminary results have to be confirmed in larger studies and more precise risk stratification tools for asymptomatic patients are needed. Novel imaging modalities such as strain and three-dimensional echocardiography could help to further improve risk stratification[16].

Based on the available data from observational studies, we suggest classifying patients into three risk categories[79,161]: (1) high risk: aborted SCD, sustained VT and VF, arrhythmic syncope; (2) moderate risk: non-sustained VT, severe structural abnormalities of RV and/or LV, presence of cardiac symptoms, ≥ 3 leads with T-wave inversions, frequent PVCs (i.e., > 760 PVC/24 h Holter) and severe disease onset age < 35 years; and (3) low risk: asymptomatic family members (also despite a positive family history of SCD), < 10 PVC/24 h Holter.

The risk factors listed here have focused largely on patients with right-dominant disease. Prognostic factors in non-classic disease still remain elusive. Patients should be astute for symptoms. Dynamic T-wave inversions, ST segment elevation and myocardial biomarker release mimicking myocardial infarction should alert the treating physicians to think of a “hot phase” of AVC. Clinical evaluation starting at age 10-12 is suggested for all first-degree relatives of AVC index patients until age 60[148]. If SCD occurs at age < 35, a full postmortem autopsy by an expert cardiac pathologist including molecular autopsy screening for genetic variants should be performed.

THERAPY

Physical activity restriction

It is a general consensus that strenuous physical activity should be avoided in symptomatic patients with AVC. There is no consensus that physical activity should be avoided in asymptomatic healthy gene carriers. A recent study has shown that endurance exercise and frequent exercise increase the risk of VT/VF and heart failure in patients, but also in healthy family members carrying a pathogenic desmosomal mutation, supporting exercise restriction for these patients[82]. We prudently advise all symptomatic patients and healthy gene carriers to refrain from practicing competitive sports and strenuous physical exercise, not only for reducing the risk of ventricular arrhythmias, but also to prevent disease onset and progression.

Pharmacological therapy

Beta-blockers, amiodarone and sotalol can be effective for treatment of sustained VT or VF in patients with AVC. However, they have no proven prognostic benefit such as ICD therapy: Wichter et al[107] proved that sotalol is highly effective to suppress VT by programmed ventricular stimulation with an efficacy of 68% and 83%, respectively, but had no effects on prognosis and SCD. Amiodarone was not superior to sotalol in this study and is not considered first-line therapy by many clinicians because of frequent side effects during long term therapy, particularly in young patients. However, recent data from the Northern American ARVC registry demonstrated amiodarone to confer the greatest efficacy in preventing ventricular arrhythmias when compared to sotalol or beta-blockers. However, mean sotalol doses were lower than in the study from Wichter et al[107] and only ten patients were treated with amiodarone in the American study. In clinical practice, beta-blockers, sotalol or amiodarone are often used as an adjunctive therapy to reduce arrhythmia burden in patient with an ICD and amiodarone is sometimes combined with beta-blockers in order to reduce sympathetic tone and mechanical wall stress[162].

Co-administration of sotalol and amiodarone is not recommended due to QT interval prolongation. Hiroi et al[108] suggest that carvedilol may control arrhythmias and improve LV function in some patients with biventricular AVC. Calcium antagonists such as verapamil and mexiletine may be effective in some patients to suppress VT but data is anecdotal. If heart failure occurs, standard therapy with beta-blockers, angiotensin converting enzyme-inhibitors and a diuretic should be established, although there are no specific studies in patients with AVC[80].

Brain natriuretic peptide, C-reactive protein, IL-1β and TNF-α as surrogate biomarkers for disease activity, inflammation and prognosis have been advocated in AVC but await further validation[58,46,164]. AVC patients at later stages have an increased risk for thromboembolism[145]. The annual incidence of thromboembolic complications, including pulmonary embolism, RVOT thrombosis and cerebrovascular events, was 0.5% in a retrospective study of 126 patients followed up for a mean period of 99 ± 64 mo[80]. Anticoagulation is often started by clinicians in the presence of severe ventricular dilation, dysfunction and aneurysm, although existing studies do not support prophylactic use in those with RV aneurysms. Data for the non-classic subtypes are lacking.

Implantable cardioverter-defibrillator

According to the ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities and its recent update[165,166], ICD implantation is indicated in patients with structural heart disease who have experienced a sustained VTA (secondary prevention, Class I indication). It is also stated that ICD implantation is reasonable in AVC patients who have at least one
risk factor for SCD (II A indication, level of evidence C). Thus, ICDs constitute a cornerstone for those patients and can prolong survival in this population. In fact, a large number of studies has demonstrated that patients with AVC who undergo ICD implantation have a high likelihood for appropriate ICD therapies\(^\text{[167]}\). However, many questions remain regarding AVC patients and their relatives who are at low to moderate risk for SCD. In these patients, a lifelong risk for lethal arrhythmias has to be weighed against the complication rates of ICDs, inadequate interventions (up to 24% within 5 years), psychological burden and economic costs of this therapy. However, complication rates seem to have declined since the use of third- or fourth-generation defibrillators. Active and young patients are at particular risk of lead displacement and inappropriate discharges for sinus tachycardia, including painful shocks and multiple invasive procedures. Thus, indiscriminate device implantation cannot be endorsed. Instead, reliable risk stratification is of paramount importance. An ICD with dual chamber detection algorithms may be wise in young patients to discriminate VT or SVT from sinus tachycardia. The use of antiarrhythmic agents can also reduce the number of inadequate interventions due to supraventricular tachyrhythmias. Furthermore, programming of higher VT/VF cut-offs and longer detection intervals can avoid inappropriate ICD shocks\(^{[168]}\). Complications of ICD therapy include a risk for perforation caused by thinning of the RV wall, lead dislodgement, R wave under-sensing and high pacing thresholds. As patients are young and mobile, these risks need particular consideration, although in one study, short and long-term risks of ICD therapy were similar to patients without AVC\(^{[169]}\).

In our clinical routine, we recommend ICD implantation for all AVC patients who have experienced a sustained VTA but we also carefully evaluate ICD implantation for primary prevention in probands and family members without documented sustained VTA. Therefore, we evaluate whether a particular patient (1) has high-risk features for SCD during follow-up (see list above), (2) whether the patient is willing to take his medication regularly and to stop competitive sports (i.e., competitive individual events like triathlon or participation in a competitive sports team), and (3) the patient’s preferences. Our threshold for ICD implantation is higher in family members and asymptomatic patients owing to the fact that previous studies have consistently shown that family members are at lower risk of experiencing sustained VTA. A possible explanation for this finding is that diagnosis occurs earlier in the disease course and once diagnosed, family members are encouraged to give up competitive sports. However, more data obtained from different well characterized AVC cohorts are necessary to assist clinicians in guiding ICD therapy.

**Catheter ablation**

Catheter ablation was first applied to treat drug-resistant VT. The application of direct current (DC) termed fulguration, used DC from a defibrillator to burn myocardial sites responsible for abnormal ventricular activation. The electric voltage was directly delivered through a catheter to the origins of VT. However, this procedure was associated with a significant risk of complications and thus rapidly abandoned. Currently accepted indications for radiofrequency catheter ablation in patients with AVC include drug-refractory VT or incessant VT with frequent ICD shocks. It should be kept in mind that, unlike in patients with idiopathic VT where catheter ablation is curative, catheter ablation in patients with AVC can only improve quality of life by decreasing the number of VT episodes and PVCs\(^{[169]}\). Catheter ablation can follow a trial of beta-blocker therapy and antiarrhythmic therapy. In some patients who do not wish long-term therapy with beta-blockers, sotalol and particularly amiodarone, catheter ablation can be performed as first line therapy. Elimination of clinical tachycardia can relieve symptoms but may not prevent SCD.

Over the last years, mapping and ablation techniques have made outstanding progress and nowadays include activation, pace and entrainment mapping during VT and substrate-based ablation using EAM that can be performed via an endocardial and epicardial approach\(^{[170]}\). Substrate-based ablation of PVCs and VT is particularly important when conventional mapping during tachycardia is not possible due to hemodynamic instability or multiple VT morphologies\(^{[171]}\). Although the initial approach involved extensive mapping to identify critical zones of slow conduction during VT, this approach has recently been replaced by a substrate-based approach. Preliminary studies have shown promising results regarding safety, arrhythmia-free survival and reduction of ICD discharges, particularly if an endocardial and epicardial approach are combined\(^{[128-131]}\). In one recent study from the Johns Hopkins cohort, the overall freedom from VT was 47%, 21% and 15% at 1, 5 and 10 years, respectively. Following epicardial VT ablation, the cumulative freedom from VT was 64% and 45% at 1 and 5 years. Of note, the VT burden decreased from a median of 0.16 VT episodes per month pre ablation to 0.08 episodes per month post ablation\(^{[172]}\). Mid-term and long-term success and safety of these methods have to be demonstrated in future studies with larger cohorts.

**Surgical methods**

Total surgical electrical RV disconnection carries an important risk of postoperative RV failure and has been practically abandoned\(^{[173]}\). If severe therapy refractory heart failure occurs, ventricular assist devices or heart transplantation have to be considered for isolated LV or biventricular failure and less frequently isolated RV failure. Some authors suggest that right heart catheterization should be performed in all cases with suspected severe RV dysfunction. If increased filling pressures suggest a Fontan-type physiology, the patient may be considered for heart transplantation\(^{[174]}\).
CONCLUSION

During the last three decades, our understanding of AVC from a developmental RV dysplasia with substitution by adipose tissue has remarkably changed to a mostly inherited polygenic disease of the intercalated disk with a broad phenotypic spectrum. Although AVC predominantly affects the RV, non-classic forms affecting the LV or both ventricles are increasingly recognized. A hallmark is the early propensity to ventricular arrhythmias associated with SCD at a young age. Enormous progress in unravelling the genetic and molecular basis of this complex disease, in which environmental factors seem to play a pivotal role, has been made in the last years. While progress in imaging and device therapy has facilitated clinical diagnosis and prevention of SCD, today’s challenges include discovery of novel genetic and environmental factors, early detection of asymptomatic patients, improved risk stratification, catheter ablation strategies and causal therapies to cure the disease. Multicenter, large, prospective follow-up studies are planned to improve our understanding of the complex underlying molecular mechanisms of AVC, which may facilitate diagnosis, risk stratification and causal therapy.

REFERENCES

1 Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, Camm AJ, Ellinor PT, Gollob M, Hamilton R, Hershberger RE, Judge DP, Le Marec H, McKenna WJ, Schulze-Bahr E, Sensmian C, Towbin JA, Watkins H, Wilde A, Wolpert C, Zipes DP. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Eur Heart J 2011; 13: 1077-1109. [PMID: 21810866 DOI: 10.1093/europace/eu245]

2 Basso C, Corrado D, Marcus FI, Nava A, Thiene G. Arrhythmogenic right ventricular cardiomyopathy. Lancet 2009; 373: 1289-1300. [PMID: 19362677 DOI: 10.1016/S0140-6736(09)60266-7]

3 Frank R, Fontaine G, Védel J, Miallet G, Sol C, Guiraudon G, Grosgeorge Y. [Electrocardiography of 4 cases of right ventricular dysplasia inducing arrhythmias]. Arch Mal Coeur Vaiss 1978; 71: 963-972. [PMID: 102297]

4 Angelini A, Basso C, Nava A, Thiene G. Endomycocardial biopsy in arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol 1996; 132: 203-206. [PMID: 8701870]

5 Richardson P, McKenna W, Bristow M, Maisch B, Maunder B, O’Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P. Report of the 1995 World Health Organization/ International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996; 93: 841-842. [PMID: 898070]

6 Basso C, Calabrese F, Corrado D, Thiene G. Postmortem diagnosis in sudden cardiac death victims: macroscopic, microscopic and molecular findings. Cardiovasc Res 2001; 50: 290-300. [PMID: 11338833]

7 Pinamonti B, Dragos AM, Pyxaras SA, Merlo M, Pivetta A, Barbagi A, Di Lenarda A, Morgera T, Mestroni L, Sinagra G. Prognostic predictors in arrhythmogenic right ventricular cardiomyopathy: results from a 10-year registry. Eur Heart J 2011; 32: 1105-1113. [PMID: 21362707 DOI: 10.1093/eurheartj/eht040]

8 Fressart V, Duthoit G, Donal E, Probst V, Deharo JC, Chevallier P, Klug D, Dubourg O, Delacretaz E, Cosnay P, Scatunchi MI, Estrambach V, Rouch-Buisson N, Hebert JL, Azarine A, Casset-Senon D, Rouzet F, Lecarpentier Y, Fontaine G, Coirault C, Frank R, Hainque B, Charron P, Desmosomal gene analysis in arrhythmogenic right ventricular dysplasia/cardiomyopathy: spectrum of mutations and clinical impact in practice. Euro pacing/europace/eur104]

9 Delmar M, McKenna WJ. The cardiac desmosome and arrhythmogenic cardiomyopathies: from gene to disease. Circ Res 2010; 107: 700-714. [PMID: 20847325 DOI: 10.1161/CIRCRESAHA.111.223412]

10 Sato PY, Coombs W, Lin X, Nekrasova O, Green KJ, Isom LL, Taffet SM, Delmar M. Interactions between ankyrin-G, Plakoglobin-2, and Connexin43 at the cardiac intercalated disc. Circ Res 2011; 109: 193-201. [PMID: 21617128 DOI: 10.1161/CIRCRESAHA.111.240723]

11 Calabrese F, Basso C, Marzorati E, Valente M, Thiene G. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: is there a role for viruses? Cardiogenes Pathol 2006; 15: 11-17. [PMID: 16414451 DOI: 10.1016/j.carpath.2005.10.004]

12 Thiene G, Corrado D, Nava A, Rossi L, Polletti A, Boffa GM, Daliento L, Pernini N. Right ventricular cardiomyopathy: is there evidence of an inflammatory aetiology? Eur Heart J 1991; 12: Suppl D: 22-25. [PMID: 1915454]

13 Chimenti C, Pieroni M, Maseri A, Frustaci A. Histologic findings in patients with clinical and instrumental diagnosis of sporadic arrhythmogenic right ventricular dysplasia. J Am Coll Cardiol 2004; 43: 2305-2313. [PMID: 15193698 DOI: 10.1016/j.jacc.2003.12.056]

14 Pieroni M, Dello Russo A, Marzo F, Pelargonio G, Casella M, Bellocci F, Crea F. High prevalence of myocarditis mimicking arrhythmogenic right ventricular cardiomyopathy differential diagnosis by electroanatomic-mapping-guided endomyocardial biopsy. J Am Coll Cardiol 2009; 53: 681-689. [PMID: 19232901 DOI: 10.1016/j.jacc.2008.11.017]

15 Corrado D, Basso C, Thiene G, McKenna WJ, Davies MJ, Fontanil, Nava A, Silvestri F, Blomstrom-Lundqvist C, Wlodarska EK. Fontaine G, Camerini GF. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy: a multicenter study. J Am Coll Cardiol 1997; 30: 1512-1520. [PMID: 9362410]

16 Gallo P, d’Amati G, Pellizzari F. Pathologic evidence of extensive left ventricular involvement in arrhythmogenic right ventricular cardiomyopathy. Hum Pathol 1992; 23: 948-952. [PMID: 1644439]

17 Azzouagh A, Churzidse S, Konorza T, Erbel R. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: a review and update. Clin Res Cardiol 2011; 100: 583-394. [PMID: 21362043 DOI: 10.1007/s00392-011-0295-2]

18 Fontaine G, Fontanil F, Hebert JL, Chemla D, Zonati O, Lecarpentier Y, Frank R. Arrhythmogenic right ventricular dysplasia. Annu Rev Med 1999; 50: 17-35. [PMID: 10073261 DOI: 10.1146/annurev.med.50.1.17]

19 Koulorus S, Pastromas S, Sakellaridou D, Kritimenos T, Manolis AS. Arrhythmogenic right ventricular cardiomyopathy in an octogenarian presenting with ventricular tachycardia. Pacing Clin Electrophysiol 2009; 32: e43-e47. [PMID: 19744268 DOI: 10.1111/j.1540-8199.2009.02540.x]

20 Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Covicoff DZ, Packer M, Clavell AL, Hayes DL, Ablett M, Trapp RJ, Underwood J, Pickering F, Truesdell J, McAtee P, Messenger J. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845-1853. [PMID: 12063368 DOI: 10.1056/NEJMoa013168]

21 Coonar AS, Protonotarios N, Tsatsopoulou A, Needham EWA, Houslton RS, Clift S, Otter MJ, Murtuza RK, McKenna WJ. Gene for arrhythmogenic right ventricular cardiomyopathy with diffuse nonepidermolytic palmoplantar keratoderma and woolly hair (Naxos disease) maps to
Kamiya A, Inagaki M, Sugimachi M, Sunagawa K. Cellular basis for trigger and maintenance of ventricular fibrillation in the Brugada syndrome model: high-resolution optical mapping study. J Am Coll Cardiol 2006; 47: 2074-2085 [PMID: 16692289 DOI: 10.1016/j.jacc.2005.12.064].

75 Norman M, Simpson M, Mogensen J, Shaw A, Hughes S, Syrris P, Sen-Chowdhry S, Rowland E, Crosby A, McKenna WJ. Novel mutation in desmoplakin causes arrhythmogenic left ventricular cardiomyopathy. Circulation 2005; 112: 636-642 [PMID: 16061754 DOI: 10.1161/CIRCULATIONAHA.104.523234].

76 Simpson MA, Cook RW, Solanki P, Patton MA, Dennis JA, Crosby AH. A mutation in NFkappaB interacting protein 1 causes cardiomyopathy and woolly haircoat syndrome of Poll Hereford cattle. Anim Genet 2009; 40: 42-46 [PMID: 19016676 DOI: 10.1111/j.1365-2052.2008.01976.x].

77 Saguner AM, Medeiros-Domingo A, Schwzyer MA, On CJ, Haegel LM, Wolber T, Hürlimann D, Steffel J, Krasnij N, Rüeger S, Held L, Lüscher TF, Brunckhorst C, Duru F. Usefulness of inducible ventricular tachycardia to predict long-term adverse outcomes in arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol 2013; 111: 250-257 [DOI: 10.1016/j.amjcard.2012.09.025].

80 Rigato I, Bause B, Rampazzo A, Zorzi A, Pilichou K, Mazzeotti E, Migliore F, Marra MP, Lorenzon A, De Bortoli M, Calore M, Nava A, Daliento L, Gregori D, Iliceto S, Thieme G, Basso C, Corrado D. Compound and digenic heterozygosity predicts lifetime arrhythmic outcome and sudden cardiac death in desmosomal gene-related arrhythmogenic right ventricular cardiomyopathy. Circ Cardiovasc Genet 2013; 6: 353-352 [PMID: 24070718 DOI: 10.1161/CIRCGENETICS.113.000286].

81 Wlodarska EK, Konka M, Zaleska T, Ploski R, Cedro K, Paciucowlata B, Bekieszinska-Figatowska M, Rydlewskaw-Sadowska W, Ruzyllo W, Hoffman P. Arrhythmogenic right ventricular cardiomyopathy in two pairs of monozygotic twins. Int J Cardiol 2005; 105: 126-133 [PMID: 16243102 DOI: 10.1016/j.ijcard.2004.11.016].

82 James CA, Bhonsale A, Tischnell C, Murray B, Madhavan S, Philips B, Russell SD, Abraham T, Tandri H, Judge DP, Calkins H. Risk stratification in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. Circ Arrhythm Electrophysiol 2013; 6: 569-578 [PMID: 23671136 DOI: 10.1161/CIRCEP.113.000253].

88 Camm CF, James CA, Tischnell C, Murray B, Bhonsale A, te Riele AS, Judge DP, Tandri H, Calkins H. Prevalence of atrial arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm 2013; 10: 1661-1668 [PMID: 23822306 DOI: 10.1016/j.hrthm.2013.03.002].

95 Cox MG, van der Zwaag PA, van der Werf C, van der Smagt JJ, Noorman M, Bhuian ZA, Wiesfeld AC, Volders PG, van Langen IM, Atsma DE, Dooijes D, van den Wijngaard van Langen IM, Atsma DE, Dooijes D, van den Wijngaard.
Corrected spelling and formatting for the reference list in the document: Saggar AM et al. Arrhythmogenic ventricular cardiomyopathy.
tional abnormalities in asymptomatic ARVC/D gene carri-
ers. J Am Soc Echocardiogr 2012; 25: 997-1006 [PMID: 22272198 DOI: 10.1016/j.echo.2012.05.008]

Vitarelli A, Cortes Moricietti M, Capotosto L, De Cicco V, Ricci F, Vitarelli M. Utility of strain echocardiography at rest and after stress testing in arrhythmogenic right ventricular dysplasia. Am J Cardiol 2013; 111: 1344-1350 [PMID: 23411103 DOI: 10.1016/j.amjcard.2013.01.279]

Daubert C, Descaves C, Foulcq JL, Bourdonnec C, Laurent M, Gouffault J. Critical analysis of cineangiographic criteria for diagnosis of arrhythmogenic right ventricular dysplasia. Am Heart J 1998; 115: 448-459 [PMID: 9341180]

Indik JH, Dallas WJ, Gear K, Tandri H, Bluemke DA, Moukabary T, Marcus FL. Right ventricular volume analysis by angiography in right ventricular cardiomyopathy. Int J Cardiovas Imaging 2012; 28: 995-1001 [PMID: 21706146 DOI: 10.1007/s10554-011-9915-1]

Corrado D, Basso C, Leoni L, Tokajuk B, Bauce B, Frigo G, Tarantini G, Napodano M, Turniri P, Ramondo A, Daliento L, Nava A, Buja G, Iliceto S, Thiene G. Three-dimensional electroanatomical voltage mapping increases accuracy of diagnosing arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 2005; 111: 3042-3050 [PMID: 15938822 DOI: 10.1161/CIRCULATIONAHA.104.486977]

Ejima K, Shoda M, Manaka T, Hagiwara N. Targeted endomyocardial biopsy using electroanatomical voltage mapping in the early stage of arrhythmogenic right ventricular cardio-
myopathy. Europace 2009; 11: 588-389 [PMID: 19168885 DOI: 10.1093/europace/eun357]

Santangeli P, Pieroni M, Dello Russo A, Casella M, Pelargonio G, Macchione A, Camporeale A, Smaldone C, Bartoletti S, Di Biase L, Bellocci F, Natala A. Noninvasive diagnosis of electroanatomical abnormalities in arrhythmogenic right ventricular
cardiomyopathy. Circ Arrhythm Electrophysiol 2010; 3: 632-638 [PMID: 20937210 DOI: 10.1161/CIRCEP.109.958116]

Marchlinski FE, Callans DJ, Gottlieb CD, Zado E. The role of endomyocardial biopsy in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circ Arrhythm Electrophysiol 2009; 2: 2715-2726 [PMID: 19382419 DOI: 10.1016/j.circap.2008.05.008]

Dalal D, Molin LH, Piccini J, Tchnell C, James C, Bomma C, Prakasa K, Towbin JA, Marcus FL, Spevak PJ, Bluemke DA, Abraham T, Russell SD, Calkins H, Judge DP. Clinical features of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2. Circulation 2006; 113: 1641-1649 [PMID: 16549640 DOI: 10.1161/CIRCULATIONAHA.105.568642]

Charron P, Arad M, Arbustini E, Basso C, Bilinska Z, Elliott P, Helio T, Keren A, McKenna WJ, Monseurat L, Pankuweit S, Perrot A, Raperetti C, Ristic A, Seggewiss H, van Langen I, Tavazzi L. Genetic counselling and testing in cardiomyo-
apathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2010; 31: 2715-2726 [PMID: 20822310 DOI: 10.1093/eurheartj/ehq271]

O'Donnell D, Gear K, Telli L, Mitchell L, Furniss S. Clinical and electrophysiological differences between patients with arrhythmogenic right ventricular dysplasia and right ventricular outflow tract tachycardia. Eur Heart J 2003; 24: 801-810 [PMID: 12727147]

Lerman BB, Stein KM, Markowitz SM, Mittal S, Slotwiner DJ. Right ventricular outflow tract tachycardia: an update. Card Electrophysiol Rev 2002; 6: 68-71 [PMID: 11984021]

Ainsworth CD, Skanes AC, Klein GJ, Gula LJ, Yee R, Krahn AD. Distinguishing arrhythmogenic right ventricular cardio-
myopathy from right ventricular outflow tract ventricular tachycardia using multilead QRS duration and axis. Heart Rhythm 2006; 3: 416-423 [PMID: 16567288 DOI: 10.1542/heart.2005.12.024]

Hofmayer KS, Machado ON, Marcus GM, Yang Y, Johnson CJ, Ernakov S, Vittinghoff E, Pandurangi U, Calkins H, Can-
nom D, Gear K, Tchnell C, Park Y, Zareba W, Marcus FL, Scheinman MM. Electrocardiographic comparison of ventri-
cular arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy and right ventricular outflow tract tachycardia. J Am Coll Cardiol 2011; 58: 831-838 [PMID: 21835319 DOI: 10.1016/j.jacc.2011.05.017]

Vasaiwala SC, Finn C, Delpriere J, Leya F, Gagermeier J, Akar JC, Santucci P, Dajani K, Bova D, Pickem MM, Basso C, Marcus FL, Wilber DJ. Prospective study of cardiac sarcoi

---

Saguner AM et al. Arrhythmogenic ventricular cardiomyopathy
mimicking arrhythmogenic right ventricular dysplasia. J Cardiovasc Electrophysiol 2009; 20: 473-476 [PMID: 19017339 DOI: 10.1111/j.1540-8167.2008.01351.x]

146 Decherger DG, Kochhäuser S, Wasmann K, Zellerhoff S, Pott C, Köbe J, Spiekter T, Piers SR, Bittmer A, Mönning G, Breithardt G, Wichter T, Zeppelinfeld K, Eckardt L. Electrophysiologic characteristics of ventricular tacharyrhythmias in cardiac sarcoidosis versus arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm 2013; 10: 158-164 [PMID: 23070261 DOI: 10.1016/j.hrtm.2012.10.019]

147 Corrado D, Leoni L, Link MS, Della Bella P, Gaia T, Cumis A, Salerno JU, Igładbashian D, Raviele A, Disertori M, Zanotto G, Verlato R, Vorgara G, Delise P, Turrini P, Basso C, Naccarrella F, Maddalena F, Estes NA, Buja G, Thieme G. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 2003; 108: 3084-3091 [PMID: 14638546 DOI: 10.1161/01.CIR.0000131030.33451.D2]

148 Quarta G, Syriss P, Ashworth M, Jenkins S, Zuberne Alapi K, Morgan J, Mair A, Pantazis A, McKenna WJ, Elliott PM. Mutations in the Lamin A/C gene mimic arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 2012; 33: 1128-1136 [PMID: 22991924 DOI: 10.1093/eurheartj/ehr451]

149 Cerrone M, Lin X, Zhang M, Agullo-Pascual E, Pfenninger A, Chkourko GUS, Hoty V, Kim C, Tirasawadichi T, Judge DP, Rothenberg E, Chen HV, Nolanito C, Priori SG, Delmar M. Missense mutations in plakoglobin-2 can cause brugada syndrome phenotype by decreasing sodium current and nav1.5 membrane localization. Heart Rhythm 2013; 10: 1743

150 Hulot JS, Jouven X, Empana JP, Frank R, Fontaine G. Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation 2004; 110: 1879-1884 [PMID: 15451782 DOI: 10.1161/01.CIR.0000143375.93288.82]

151 Corrado D, Basso C, Pavei A, Michieli P, Schiavon M, Thieme G. Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. JAMA 2006; 296: 1593-1601 [PMID: 17018804 DOI: 10.1001/jama.296.13.1593]

152 Pelzer T, Schumann M, Neumann M, dejager T, Stimpel M, Serfling E, Neyes L. 17beta-estradiol prevents programmed cell death in cardiac myocytes. Biochem Biophys Res Commun 2000; 269: 192-200 [PMID: 10652235 DOI: 10.1006/bbrc.2000.2073]

153 Lemola K, Brunckhorst C, Hellenstein U, Oechslin E, Jenni R, Duru F. Predictors of adverse outcome in patients with arrhythmogenic right ventricular cardiomyopathy: a study of patients with arrhythmogenic right ventricular cardiomyopathy and subclinical right ventricular dysfunction. Eur Heart J 2011; 32: 1089-1096 [PMID: 21406439 DOI: 10.1093/eurheartj/ehr069]

154 Corrado D, Basso C, Pilichou K, Thiene G. Molecular biology and clinical management of arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart 2011; 97: 530-539 [PMID: 20900047 DOI: 10.1136/hrt.2010.192767]

155 Calcines H. Arrhythmogenic right-ventricular dysplasia/cardiomyopathy. Curr Opin Cardiol 2006; 21: 55-63 [PMID: 16355031 DOI: 10.1016/j.cocar.2006.02.002]

156 Hiroi Y, Fuji Y, Komatsu S, Sonoda M, Sakamura Y, Imai Y, Oishi Y, Nakamura F, Ajiki K, Hayami N, Murakawa Y, Ohno M, Hira K, Ohmo Y, Ohtomo K, Nagai R. Carvedilol therapy improved left ventricular function in a patient with arrhythmogenic right ventricular cardiomyopathy. Jpn Heart J 2004; 45: 169-177 [PMID: 14973367]

157 Matsuo K, Nishikimi T, Yutani C, Kurita T, Shimizu W, Taguchi A, Suyama K, Aihara N, Kamakura S, Kawagata T, Takamini M, Shimomura K. Diagnostic value of plasma levels of brain natriuretic peptide in arrhythmogenic right ventricular dysplasia. Circulation 1998; 98: 2433-2440 [PMID: 9852849]

158 Epstein AE, Dimarco JP, Ellenbogen KA, Estes NA, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. Heart Rhythm 2008: 5: e1-62 [PMID: 18534360 DOI: 10.1016/j.hrthm.2008.04.014]

159 Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammil SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2013; 127: e230-e352 [PMID: 23255456 DOI: 10.1161/CIR.0b013e3182860b9a]

160 Schuler PK, Haegeli LM, Saguner AM, Wolber T, Tanner FC, Jenni R, Corti N, Lüscher TF, Brunckhorst C, Duru F. Predictors of appropriate ICD therapy in patients with arrhythmogenic right ventricular cardiomyopathy: long term experience of a tertiary care centre. PLoS One 2012; 7: e39584 [PMID: 23028419 DOI: 10.1371/journal.pone.0039584]

161 Veitmann C, Kuschyk J, Schimph R, Streitner F, Snoehe N, Borggreve M, Wolpert C. Prevention of inappropriate ICD
shocks in patients with Brugada syndrome. Clin Res Cardiol 2010; 99: 37-44 [PMID: 19760052 DOI: 10.1007/s00392-009-0075-4]

169 Zou J, Cao K, Yang B, Chen M, Shan Q, Chen C, Li W, Haines DE. Dynamic substrate mapping and ablation of ventricular tachycardias in right ventricular dysplasia. J Interv Card Electrophysiol 2004; 11: 37-45 [PMID: 15273453 DOI: 10.1023/B:JICE.0000035928.54293.42]

170 Arbelo E, Josephson ME. Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia. J Cardiovasc Electrophysiol 2010; 21: 473-486 [PMID: 20132999 DOI: 10.1111/j.1540-8167.2009.01694.x]

171 Verma A, Kilicaslan F, Schweikert RA, Tomassoni G, Rossillo A, Marronche NF, Oxduran V, Wazni OM, Elayi SC, Saenz LC, Minor S, Cummings JE, Burkhardt JD, Hao S, Beheiry S, Tchou PJ, Natale A. Short- and long-term success of substrate-based mapping and ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia. Circulation 2005; 111: 3209-3216 [PMID: 15956125 DOI: 10.1161/CIRCULATIONAHA.104.510803]

172 Philips B, Madhavan S, James C, Tichnell C, Murray B, Dalal D, Bhonsale A, Nazarian S, Judge DP, Russell SD, Abraham T, Calkins H, Tandri H. Outcomes of catheter ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Arrhythm Electrophysiol 2012; 5: 499-505 [PMID: 22492430 DOI: 10.1161/CIRCEP.111.968677]

173 Guiraudon GM, Klein GJ, Sharma AD, Yee R, Guiraudon CM. Surgical therapy for arrhythmogenic right ventricular adiposis. Eur Heart J 1989; 10 Suppl D: 82-83 [PMID: 2806309]

174 Gilljam T, Bergh CH. Right ventricular cardiomyopathy: timing of heart transplantation in Uhl’s anomaly and arrhythmogenic right ventricular cardiomyopathy. Eur J Heart Fail 2009; 11: 106-109 [PMID: 19147464 DOI: 10.1093/eurhjhf/hfn014]

175 Kim C, Wong J, Wen J, Wang S, Wang C, Spiering S, Kan NG, Forcales S, Puri PL, Leone TC, Marine JE, Calkins H, Kelly DP, Judge & Huei-Sheng Vincent Chen DP. Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature 2013; 494: 105-110 [DOI: 10.1038/nature11799]